



Advances in Radiotherapy for Head and Neck Cancer

Guest Editor:

Dr. Francesca De Felice

Department of Radiological
Sciences, Oncology and
Anatomical Pathology, Sapienza,
“Sapienza” University of Rome,
00185 Rome, Italy

Deadline for manuscript
submissions:

closed (25 October 2024)

Message from the Guest Editor

Dear Colleagues,

Radio(chemo)therapy is a standard of care, both in primary and adjuvant settings, in the treatment of head and neck cancer. Efficacy improvements mainly originate from the introduction of technical advances, altered fractionation regimens, new concomitant administration of targeted drugs, and integration of molecular imaging in target volume delineation.

The aim of this Special Issue is to present a series of original (pre)clinical trials/translational studies/review articles that will highlight the progress that has been made in the management of head and neck cancer.

The topics of interest include, but are not limited to, the following: chemoradiotherapy; radioimmunotherapy; hypoxia and radiotherapy; stereotactic radiotherapy; patient-reported outcome and radiotherapy; de-escalation strategies; proton therapy; flash therapy; follow-up strategies; biomarker and patient stratification.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)